The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma

Hypopharyngeal Carcinoma Clinical Trial

Official title:

The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma: A Multi-center Randomized Controlled Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05494190
• Other study ID #: EENTHN0706
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: November 2025

Study information

• Verified date: April 2023
• Source: Eye & ENT Hospital of Fudan University
• Contact: Feiran Li
• Phone: 8621-64377151
• Email: lifr214[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

Description:

Hypopharyngeal squamous cell carcinoma (HPSCC) is prone to have regional metastasis, which is an established negative prognostic factor. Especially for N2/3 patients whose metastatic neck nodes are bulky and have multiple or extracapsular spreads, their survival outcome is even worse. Therefore, it is vital for clinicians to select proper treatment and further improve the prognosis of N2/3 HPSCC patients. The aim of this randomized controlled prospective study is to explore the suitable treatment strategy of metastatic neck nodes in N2/3 HPSCC. This study will enroll a total of 111 HPSCC patients, who are clinically classified as T1/2 N2/3 M0 stage and initially treated with surgery (group 1) or induction chemotherapy (group 2). For patients with the regional response of PR<50%/SD/PD after induction chemotherapy, their following treatment will be surgery for both the primary and regional sites. For patients with the regional response of CR/PR≥50%, the following treatment will be concomitant chemoradiotherapy for both the primary and regional sites.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 111
• Est. completion date: November 2025
• Est. primary completion date: November 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Able to understand and willing to sign a written informed consent document.

2. Age = 18 and = 75 years.

3. Male or female.

4. Karnofsky physical status (KPS): = 80

5. Hepatic function, renal function and normal blood test. Hepatic function: Alanine aminotransferase (ALT) = 2.5 upper limit of normal, Aspartate aminotransferase (AST) = 2.5 upper limit of normal. Serum total bilirubin = 1.5 upper limit of normal. Kidney function: Serum creatinine < upper limit of normal value and creatinine clearance rate > 60 ml/(min*1.73m2) (Cockcroft-Gault formula). Blood test: neutrophil (Neu) = 1.5×109/L, platelet (PLT) = 100×109/L, hemoglobin (HGB) = 90 g/L.

6. Pathologically diagnosed with squamous cell carcinoma of the hypopharynx.

7. After clinical and radiographic evaluations, clinically classified as T1/2 N2/3 M0 stage according to American Joint Committee on Cancer (AJCC, eighth edition).

8. Resectable regional metastatic lesion (incompletely tumor- wrapped carotid vascular).

9. Assessable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1).

10. Radical treatment intent.

11. Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin. Female patients who do not have fertility (ie meet at least one of the following criteria): Have undergone hysterectomy and/or bilateral oophorectomy with archival records, medically confirmed ovarian function decline; In postmenopausal state. It is defined as: At least 12 months of continuous menstruation without other pathological or physiological reasons, and the status confirmed by serum follicle stimulating hormone (FSH) levels is consistent with postmenopausal status.

12. Good compliance.

Exclusion Criteria:

1. Distant metastatic disease

2. Have a history of other cancers or coinstantaneous second primary tumor

3. Previous treatment for the primary tumor, including radiotherapy, surgery except biopsy operation, chemotherapy, immunotherapy and biological targeted therapy.

4. Patients who have participated in other clinical trials within 1 month before the test.

5. Patients estimated to have poor tolerance to induction chemotherapy.

6. The investigator believes that it is inappropriate for individuals to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time [within the past year] or active suicidal ideation or behavior).

7. Palliative treatment intent.

8. Pregnant or lactating women.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Hypopharyngeal Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Docetaxel
60 mg/m2 i.v. day 1
• Cisplatin
60 mg/m2 i.v. day 1-3
• Capecitabine
750 mg/m2 po bid day 1-14

Radiation:
• Concomitant chemoradiotherapy
Radiotherapy: using intensity-modulated radiation therapy (IMRT) Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0~2.2 Gy per day, 5 days per week Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65~70 Gy in total, 1.7~2.0 Gy per day, 5 days per week Prophylactic irradiation for sites of suspected subclinical spread: 50~60 Gy in total, 1.7~2.0 Gy per day, 5 days per week Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks.

Procedure:
• Surgery
Neck dissection and primary tumor resection

Locations

Country	Name	City	State
China	Harbin Medical University Cancer Hospital	Harbin	Heilongjiang
China	Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University	Jinan	Shandong
China	Eye & ENT Hospital, Fudan University	Shanghai	Shanghai

Sponsors (3)

Lead Sponsor	Collaborator
Eye & ENT Hospital of Fudan University	Harbin Medical University Third Affiliated Hospital, Shandong Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival rate	The proportion of patients with disease progress or death due to any reasons.	3 years
Secondary	Overall survival rate	The proportion of dead patients due to any reasons.	3 years
Secondary	Local control	The proportion of patients with local recurrence.	3 years
Secondary	Regional control	The proportion of patients with regional recurrence.	3 years
Secondary	Metastasis-free survival	The proportion of patients with distant metastasis.	3 years
Secondary	Quality of life (UW-QOL V4.0)	Evaluated by University of Washington Quality of Life Questionnaire (UW-QOL) V4.0.	3 years
Secondary	Adverse events	Evaluated by the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) V5.0.	3 years